Patient organizations from across Europe and beyond are calling on the Czech government and the EU to publish evidence and consult with patients before considering CBD a “drug precursor” — and to properly regulate it, rather than quietly restricting it.
PRAGUE, June 17, 2026 — A group of patient organizations from across Europe and beyond today launched an appeal and public petition titled “Care from Discrimination is a Human Right,” defending patients’ rights and challenging efforts to treat CBD as if it were a “drug precursor.”
Czech authorities are considering measures regarding CBD as a precursor: including including the substance on the European list of precursors and restricting the ways it can be processed under Czech law. Before that happens, the coalition is asking for something simple: to publish the evidence, talk to the patients affected, and make decisions openly.
The petition is available on CBD Human Right and the appeal is published in six languages. It is launched just hours before the meeting of the Czech government's Drug Policy Council, which takes place on the afternoon of June 17.
Why does it matter?
CBD itself is not controlled under international drug control conventions, and a pure CBD-based medicine is already approved in the EU for the treatment of severe forms of epilepsy. Mere presumption is not enough to justify a blanket ban – and according to the International Narcotics Control Board (INCB) itself, the evidence that CBD is actually used to produce illegal semi-synthetic cannabinoids is “limited”.
There’s also a practical problem. The truly dangerous products—synthetic and semi-synthetic cannabinoids sold through gray market channels—require direct regulatory enforcement, age restrictions, and quality rules. If you push tested CBD out of legal stores, demand won’t go away; it will shift to the unregulated market, where contamination with heavy metals, pesticides, and solvents is much harder to detect.

Patients are not asking for a loophole. We are asking not to be pushed into the shadows. If the government believes that CBD should be restricted, let it present the evidence, listen to the patients affected, and explain why the current rules are not enough. Care without discrimination means making decisions in the light. – MUDr. Pavel Kubů , KOPAC (Association of Patients for Cannabis Treatment), Czech Republic
The coalition is trying to make clear what its position is not. This is not an anti-regulation campaign. It supports quality standards, testing for contaminants, honest labeling, age limits, and real enforcement against dangerous synthetic products. What it rejects, however, is tacit administrative short-cuts based on evidence that no one has published.
What the coalition demands
The appeal calls on the Czech government, EU institutions and UN drug control agencies to:
1. publish evidence before any CBD restrictions are imposed;
2. avoid hidden or purely administrative measures that circumvent public scrutiny;
3. respect the autonomy, dignity and right of patients to make informed decisions;
4. prioritize appropriate regulation over bans;
5. Focus law enforcement on dangerous synthetic and semi-synthetic products;
6. consulted with patient organizations before making decisions.
Sign the appeal
The petition is available at CBD Human Right . The full text of the appeal, supporting evidence and press materials can be found at CBD Human Right.
About the initiative "Care from discrimination is a human right"
“Care from Discrimination is a Human Right” is an open coalition of patient organizations: Aube (Canada), Centrum Paraple (Czech Republic), Dosemociones (Spain), Fuck Cancer (Czech Republic), KOPAC (Czech Republic), Mothers for Cannabis (Portugal), PatientsCann (United Kingdom) and Verein Medcan (Switzerland), with others joining.
The Care Without Discrimination is a Human Right Coalition campaigns on health policy and patient rights. It does not promote, sell or refer to any CBD products.
The official title of the call is “Care from Discrimination — Patients’ Rights and the Proposed CBD Restriction.”
media Contact
media@cbdhumanright.org — spokespersons are available in English, Czech, Spanish, French, German, and Italian. We respond within one business day, and even faster during procedural deadlines.
Notes
- The call is available in English (EN), Czech (CZ), Spanish (ES), French (FR), German (DE) and Italian (IT) on cbdhumanright.org and in a downloadable press kit.
- Primary sources include the World Health Organization (WHO) ECDD critical review (2018), the Court of Justice of the European Union (CJEU) judgment in the Kanavape case (C-663/18, 2020), the European Medicines Agency (EMA) assessment of Epidyolex, the International Narcotics Control Board (INCB) report on precursors 2025 (E/INCB/2025/4), and the European Union Drugs Agency (EUDA) materials on semi-synthetic cannabinoids.
- In the Kanavape case, the Court of Justice of the EU ruled that a Member State may not prohibit the placing on the market of CBD if it was legally produced in another Member State, unless such a restriction is necessary and proportionate. In this case, the CBD was produced in the Czech Republic.
- HHC was added to Schedule II of the 1971 Convention on Psychotropic Substances by the United Nations Commission on Narcotic Drugs in 2025, effective December 6, 2025.















1 Comment
Thank you very much for this initiative. Banning CBD is nonsense.